Selective MMP-inhibition with Ro 28-2653 in acute experimental stroke - A magnetic resonance imaging efficacy study

Brain Research

Volumn 1368, Issue , 2011, Pages 264-270

  Nagel, S ^a   Heinemann, P V ^a   Heiland, S ^a   Koziol, J ^b   Gardner, H ^b,c   Wagner, S ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

BBB breakdown; Focal cerebral ischemia; Metalloproteinases; Middle cerebral artery occlusion; MRI

Indexed keywords

GADOLINIUM PENTETATE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; RO 28 2653; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG SELECTIVITY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; REPERFUSION; SCORING SYSTEM; STROKE; TREATMENT DURATION;

ANIMALS; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; EDEMA; INFARCTION, MIDDLE CEREBRAL ARTERY; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PIPERAZINES; PYRIMIDINES; RATS; RATS, WISTAR; REPERFUSION; STROKE; TIME FACTORS; TREATMENT OUTCOME;

RATTUS;

EID: 78651095234     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.10.057     Document Type: Article

References (27)

1. C. Abramjuk, K. Jung, H.W. Krell, R. Juchem, R. Peters, K. Taymoorian, A. Staack, C. Stephan, J. Schnorr, S.A. Loening, and M. Lein Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats Anticancer Drugs 16 2005 855 861
2. M. Asahi, K. Asahi, J.C. Jung, G.J. del Zoppo, M.E. Fini, and E.H. Lo Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94 J. Cereb. Blood Flow Metab. 20 2000 1681 1689
3. B.S. Aspey, F.L. Taylor, M. Terruli, and M.J. Harrison Temporary middle cerebral artery occlusion in the rat: consistent protocol for a model of stroke and reperfusion Neuropathol. Appl. Neurobiol. 26 2000 232 242
4. A.L. Busza, K.L. Allen, M.D. King, N. van Bruggen, S.R. Williams, and D.G. Gadian Diffusion-weighted imaging studies of cerebral ischemia in gerbils. Potential relevance to energy failure Stroke 23 1992 1602 1612
5. L.M. Coussens, B. Fingleton, and L.M. Matrisian Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 295 2002 2387 2392
6. B.J. Dardzinski, C.H. Sotak, M. Fisher, Y. Hasegawa, L. Li, and K. Minematsu Apparent diffusion coefficient mapping of experimental focal cerebral ischemia using diffusion-weighted echo-planar imaging Magn. Reson. Med. 30 1993 318 325
7. M. Fujimura, Y. Gasche, Y. Morita-Fujimura, J. Massengale, M. Kawase, and P.H. Chan Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion Brain Res. 842 1999 92 100 (Pubitemid 29447856)
8. J.H. Garcia, S. Wagner, K.F. Liu, and X.J. Hu Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats Stroke 26 1995 627 635
9. F. Grams, H. Brandstetter, S. D'Alo, D. Geppert, H.W. Krell, H. Leinert, V. Livi, E. Menta, A. Oliva, G. Zimmermann, F. Gram, and V.E. Livi Pyrimidine-2, 4, 6-Triones: a new effective and selective class of matrix metalloproteinase inhibitors Biol. Chem. 382 2001 1277 1285
10. M. Hoehn-Berlage, M. Eis, T. Back, K. Kohno, and K. Yamashita Changes of relaxation times (T1, T2) and apparent diffusion coefficient after permanent middle cerebral artery occlusion in the rat: temporal evolution, regional extent, and comparison with histology Magn. Reson. Med. 34 1995 824 834
11. S. Horstmann, P. Kalb, J. Koziol, H. Gardner, and S. Wagner Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies Stroke 34 2003 2165 2170
12. M. Kilian, J.I. Gregor, I. Heukamp, M. Hanel, M. Ahlgrimm, I. Schimke, G. Kristiansen, A. Ommer, M.K. Walz, C.A. Jacobi, and F.A. Wenger Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: inhibition of matrix metalloproteinases in pancreatic cancer Prostaglandins Leukot. Essent. Fatty Acids 75 2006 429 434
13. M. Lein, K. Jung, B. Ortel, C. Stephan, W. Rothaug, R. Juchem, M. Johannsen, S. Deger, D. Schnorr, S. Loening, and H.W. Krell The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model Oncogene 21 2002 2089 2096
14. E.Z. Longa, P.R. Weinstein, S. Carlson, and R. Cummins Reversible middle cerebral artery occlusion without craniectomy in rats Stroke 20 1989 84 91
15. S. Lorenzl, S. Narr, B. Angele, H.W. Krell, J. Gregorio, M. Kiaei, H.W. Pfister, and M.F. Beal The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice Exp. Neurol. 200 2006 166 171
16. D. Mangoldt, B. Sinn, M. Lein, H.W. Krell, D. Schnorr, S.A. Loening, and K. Jung The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells Apoptosis 7 2002 217 220
17. H. Nagasawa, and K. Kogure Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion Stroke 20 1989 1037 1043
18. S. Nagel, J. Genius, S. Heiland, S. Horstmann, H. Gardner, and S. Wagner Diphenyleneiodonium and dimethylsulfoxide for treatment of reperfusion injury in cerebral ischemia of the rat Brain Res. 1132 2007 210 217
19. S. Nagel, Y. Su, S. Horstmann, S. Heiland, H. Gardner, J. Koziol, F.J. Martinez-Torres, and S. Wagner Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase Brain Res. 1188 2008 198 206
20. J.R. Opalka, F.N. Gellerich, L. Kling, B. Muller-Beckmann, and S. Zierz Effect of the new matrix metalloproteinase inhibitor RO-28-2653 on mitochondrial function Biochem. Pharmacol. 63 2002 725 732
21. C.M. Overall, and C. Lopez-Otin Strategies for MMP inhibition in cancer: innovations for the post-trial era Nat. Rev. Cancer 2 2002 657 672
22. M. Piette, B. Evrard, F. Frankenne, P. Chiap, P. Bertholet, D. Castagne, J.M. Foidart, L. Delattre, and G. Piel Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions Eur. J. Pharm. Sci. 28 2006 189 195
23. A.M. Romanic, R.F. White, A.J. Arleth, E.H. Ohlstein, and F.C. Barone Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size Stroke 29 1998 1020 1030
24. G.A. Rosenberg, M. Navratil, F. Barone, and G. Feuerstein Proteolytic cascade enzymes increase in focal cerebral ischemia in rat J. Cereb. Blood Flow Metab. 16 1996 360 366
25. G.A. Rosenberg, E.Y. Estrada, and J.E. Dencoff Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain Stroke 29 1998 2189 2195
26. V.W. Yong, C. Power, P. Forsyth, and D.R. Edwards Metalloproteinases in biology and pathology of the nervous system Nat. Rev. Neurosci. 2 2001 502 511
27. B.Q. Zhao, S. Wang, H.Y. Kim, H. Storrie, B.R. Rosen, D.J. Mooney, X. Wang, and E.H. Lo Role of matrix metalloproteinases in delayed cortical responses after stroke Nat. Med. 12 2006 441 445